このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Maravai LifeSciences Holdings マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Trey Martin

最高経営責任者

US$2.3m

報酬総額

CEO給与比率	32.6%
CEO在任期間	less than a year
CEOの所有権	0.2%
経営陣の平均在職期間	2.1yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Maravai LifeSciences Holdings の収益と比較して、Trey Martin の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$131m
Dec 31 2023	US$2m	US$750k	-US$119m
Sep 30 2023	n/a	n/a	US$25m
Jun 30 2023	n/a	n/a	US$75m
Mar 31 2023	n/a	n/a	US$153m
Dec 31 2022	US$15m	US$660k	US$220m

報酬と市場: Treyの総報酬 ($USD 2.30M ) は、 German市場 ($USD 1.53M ) の同規模の企業の平均を上回っています。

報酬と収益: Treyの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Trey Martin (49 yo)

less than a year

在職期間

US$2,301,864

報酬

Mr. William E. Martin, III, also known as Trey, was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. since December 5, 2022 until July 27, 2023 and is its Chief Executive Office...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Carl Hull	Co-Founder & Executive Chairman	3.7yrs	US$5.22m	0.22% $ 3.6m
William Martin	Chief Executive Officer	less than a year	US$2.30m	0.16% $ 2.6m
Kevin Herde	Executive VP & CFO	7.2yrs	US$2.79m	0.022% $ 361.8k
Peter Leddy	Executive VP & Chief Administrative Officer	2.1yrs	US$2.83m	0.030% $ 489.0k
Christine Dolan	Executive VP & GM of Cygnus Technologies	6.8yrs	US$2.26m	0.020% $ 318.4k
Andrew Burch	President of Nucleic Acid Production	1.3yrs	US$2.99m	0.024% $ 390.9k
Debra Hart	Senior Director of Investor Relations	no data	データなし	データなし
Kurt Oreshack	Executive VP	3.7yrs	US$701.40k	0.019% $ 312.9k
Rebecca Buzzeo	Executive VP & Chief Commercial Officer	1.4yrs	データなし	0.015% $ 240.7k
Kate Broderick	Chief Innovation Officer	1.4yrs	データなし	データなし

2.1yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: MARの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Carl Hull	Co-Founder & Executive Chairman	3.7yrs	US$5.22m	0.22% $ 3.6m
John DeFord	Independent Director	less than a year	US$435.03k	データなし
Constantine Mihas	Non-Independent Director	3.7yrs	US$370.48k	0.0032% $ 52.3k
Sean Cunningham	Non-Independent Director	3.7yrs	US$367.98k	0.0032% $ 52.3k
Gregory Lucier	Independent Director	3.7yrs	US$360.48k	0.023% $ 380.6k
Susannah Gray	Independent Director	3.7yrs	US$395.48k	0.027% $ 441.7k
Benjamin Daverman	Non-Independent Director	3.7yrs	US$360.48k	0.0032% $ 52.3k
Luke Marker	Non-Independent Director	3.7yrs	US$360.48k	0.0032% $ 52.3k
Murali Prahalad	Independent Director	3.7yrs	US$367.98k	0.016% $ 254.7k
Jessica Hopfield	Independent Director	3.7yrs	US$387.98k	0.050% $ 808.7k
Anat Ashkenazi	Independent Director	3.7yrs	US$392.98k	0.012% $ 197.2k

3.7yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: MARの取締役会は経験豊富であると考えられます ( 3.6年の平均在任期間)。

Maravai LifeSciences Holdings マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. Announces Board Changes

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Small Cap Comp Value Index

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.091 loss per share (vs US$0.001 loss in 1Q 2023)

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai LifeSciences Holdings, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$0.90 loss per share (vs US$1.67 profit in FY 2022)

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Investor sentiment deteriorates as stock falls 16%

Maravai LifeSciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings released: US$0.049 loss per share (vs US$0.34 profit in 3Q 2022)

Now 27% undervalued after recent price drop

Maravai LifeSciences Holdings, Inc. Provides Updated Earnings Guidance for the Full Year 2023

Maravai LifeSciences Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 15%

Maravai Lifesciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: US$0.05 loss per share (vs US$0.54 profit in 2Q 2022)

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Maravai LifeSciences Holdings, Inc. Announces Board Changes

New major risk - Share price stability

Investor sentiment improves as stock rises 25%

First quarter 2023 earnings released: US$0.001 loss per share (vs US$0.51 profit in 1Q 2022)

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$1.67 (vs US$1.59 in FY 2021)

Maravai LifeSciences Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Investor sentiment deteriorated over the past week

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$0.46 in 3Q 2021)

Investor sentiment deteriorated over the past week

Maravai Lifesciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation

Maravai LifeSciences Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Investor sentiment deteriorated over the past week

Maravai LifeSciences Announces CEO Leadership Transition

Investor sentiment improved over the past week

Maravai Lifesciences Holdings, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.44 in 2Q 2021)

Maravai LifeSciences Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Maravai LifeSciences, Inc. Appoints Peter Leddy as Executive Vice President and Chief Administrative Officer

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: US$0.51 (vs US$0.24 in 1Q 2021)

Maravai LifeSciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Maravai LifeSciences Holdings, Inc. to Report Q1, 2022 Results on May 05, 2022

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 12, 2022

Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay

Investor sentiment improved over the past week

Maravai Lifesciences Holdings, Inc. Revised Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$0.47 (vs US$0.62 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Maravai LifeSciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $1 billion.

Maravai LifeSciences Holdings, Inc. Provides Financial Guidance for the Year 2021

Second quarter 2021 earnings released: EPS US$0.44 (vs US$0.021 loss in 2Q 2020)

Investor sentiment improved over the past week

Co-Founder, President & Executive VP of Corporate Development Eric Tardif has left the company

Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: EPS US$0.24 (vs US$0.021 loss in 1Q 2020)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /34